Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-02-25Clinical Trial Update: Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease [Phase 4]
Clinical trial update describing a Phase 4 study evaluating the efficacy and safety of the Ledipasvir/Sofosbuvir fixed-dose combination for …
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection [Phase 2]
Phase 2 trial evaluating the combination of simeprevir and sofosbuvir in treatment-naïve or experienced adults with chronic genotype 4 hepat…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation [Phase 2]
Phase 2 trial evaluating sofosbuvir and ribavirin in adults with chronic hepatitis C and cirrhosis, including patients with portal hypertens…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 [Phase 4]
This is a Phase 4 randomized, open-label trial comparing pegylated interferon alfa-2a with adjusted-dose ribavirin to standard therapy in tr…
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: HCV/HIV Coinfection: Antiviral Therapy and Fibrosis
A completed Johns Hopkins University clinical trial studied antiviral therapy for HIV and Hepatitis C coinfection with a focus on liver fibr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-02-24Clinical Trial Update: Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV [Phase 2]
A Phase 2 clinical trial conducted at Cairo University evaluating Biobran MGN-3 (arabinoxylan rice bran) in combination with Interferon-Alph…
-
CLINICAL_TRIALS trial_result · 2016-02-23Clinical Trial Update: Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059) [Phase 4]
Phase 4 trial evaluating short course peginterferon alfa-2b plus ribavirin in chronic hepatitis C genotype 4 patients who achieved rapid vir…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before [Phase 3]
A Phase 3 trial evaluating the efficacy and safety of three experimental hepatitis C therapies compared with Telaprevir in treatment-naive a…
-
CLINICAL_TRIALS trial_result · 2016-02-22Clinical Trial Update: An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
An observational study evaluating peginterferon-based triple therapy for chronic hepatitis C genotype 1; the study is completed and results …
-
CLINICAL_TRIALS research · 2016-02-22Clinical Trial Update: A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
This clinical trial update describes a study examining patient characteristics, health care management, and health outcomes of hepatitis C p…
-
CLINICAL_TRIALS withdrawal · 2016-02-22Clinical Trial Update: Chronic Hepatitis B and C Recall Northern Holland
A clinical trial in Northern Holland involving Hepatitis B and Hepatitis C is being recalled/withdrawn; status is currently UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2016-02-18Clinical Trial Update: Risk of Post Transfusion Hepatitis C Virus Infection
A completed NHLBI clinical trial assesses the risk of hepatitis C virus infection after blood transfusion.
-
FDA approval · 2016-02-17FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
FDA approved a supplemental application for Ledipasvir and Sofosbuvir (Asegua Therapeutics LLC). This action concerns the hepatitis C therap…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients [NA]
A completed study evaluating the combination of alisporivir (Debio 025) with pegylated interferon alfa-2a and ribavirin in treatment-naïve p…
-
CLINICAL_TRIALS trial_result · 2016-02-15Clinical Trial Update: A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients
A completed clinical trial in Slovenian patients with chronic hepatitis C evaluating peginterferon alfa-2a (Pegasys) in combination with rib…
-
FDA approval · 2016-02-12FDA Approved: LEDIPASVIR AND SOFOSBUVIR — Supplemental Application (Asegua Therapeutics LLC)
FDA approved a supplemental NDA for Ledipasvir and Sofosbuvir from Asegua Therapeutics LLC, approving a generic combination product for hepa…
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 [Phase 3]
Phase 3 study of BI 207127 in combination with faldaprevir and ribavirin for hepatitis C, including peginterferon-ineligible patients; resul…
-
CLINICAL_TRIALS research · 2016-02-12Clinical Trial Update: Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure
A completed epidemiological study evaluated how patients with chronic hepatitis C and prior treatment failure are managed.
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults [Phase 3]
Phase 3 trial evaluating three experimental hepatitis C drugs against Telaprevir in treatment-experienced adults has completed with results …
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
An observational study evaluating peginterferon alfa-2a plus ribavirin for hepatitis C in Austria has completed, with results posted in 2016…
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
An observational study evaluating the effects of cumulative ribavirin dose in participants with chronic hepatitis C; the trial has completed…
-
CLINICAL_TRIALS research · 2016-02-10Clinical Trial Update: The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
An in-vitro study, sponsored by George Washington University, investigated whether HIV Tat protein influences Hepatitis C replication; the s…
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C [Phase 1]
A Phase 1 study evaluating autoinjector versus pre-filled syringe administration of Peginterferon alfa-2a (Pegasys) for chronic hepatitis C;…
-
CLINICAL_TRIALS trial_result · 2016-02-05Clinical Trial Update: SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection [Phase 3]
Phase 3 trial evaluating sofosbuvir-based regimens with ribavirin for 16 or 24 weeks and with pegylated interferon for 12 weeks in adults wi…
-
CLINICAL_TRIALS trial_result · 2016-02-04Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) [Phase 1]
Phase 1 trial update evaluating safety, pharmacokinetics, and pharmacodynamics of MK-8876 in participants with hepatitis C infection has com…